Experts In Vasectomy and Urological Treatments

Dr. Snoy is a general urologist. In addition to vasectomies he also treats:
• Bladder control
• Overactive bladder
• Bladder cancer
• Urinary incontinence
• Kidney stones
• Prostate disorders
• Prostate cancer
• Erectile dysfunction

Dr. Snoy’s Curriculum Vitae


Frederick J. Snoy, MD, FACS
Urology Group of New Mexico, PC
4161 Montgomery Blvd. NE
Albuquerque, New Mexico 87109

 

Education:

Secondary:

Park Tudor School, 1967-1971
Indianapolis, Indiana

Undergraduate:

Regis College, 1971-1975
Denver, Colorado
Bachelor of Science, Biology

Graduate:

Indiana State University, 1975 -1976
Terre-Haute, Indiana
Master of Arts, Cardiac Physiology

Medical:

Indiana University School of Medicine, 1976-l980
Indianapolis, Indiana

Medical School Activities:

  • Medical Physiology Lab Instructor
  • Medical Education on Substance Abuse Program
  • AMSA Member
  • Sigma Xi
  • Phi Rho Sigma Medical Society
  • OSR Representative to the AMA, 1978-1980

 

Residency:

Surgical Internship and Residency, 1980-1982
University of New Mexico Affiliated Hospitals

Urology Residency, 1982-1985
University of New Mexico Affiliated Hospitals

 

Post Graduate Courses:

  • Extracorporeal Shock Wave Lithotripsy, November 1988
  • Lasers In Urology, March 1989
  • Urologic Ultrasound, October 1989
  • Contigen Implant Training Program, 1994
  • Urologic Laparoscopy Course, 1992, 1994
  • Erectile Dysfunction,, Peyronie’s Disease and Priapism, 1994, 1997, 1999
  • Urodynamics, December 1995
  • Evaluation and Management of Infertile Male, May 1996
  • Practical Urodynamics, May 1996
  • Genitourinary Trauma, May 1996
  • Andropause, April 2000
  • Laparoscopic Surgery Course, October 2001
  • Prostate Brachytherapy Course, January 2002

 

Fellowships:

Fellow, American College of Surgeons

 

Board Certification:

American Board of Urology

 

State Licensure:

Indiana and New Mexico, NM 80-262, expires 07/01/14

 

Current Employment:

1985-present Urology Group of New Mexico, PC
Albuquerque, New Mexico

 

University Appointment:

Clinical Instructor of Urology
University of New Mexico

 

Hospital Staff Appointments:

West Mesa Medical Center
Albuquerque, New Mexico

Albuquerque Regional Medical Center
Albuquerque, New Mexico

Northeast Heights Medical Center
Albuquerque, New Mexico

Presbyterian Hospital
Albuquerque, New Mexico

University of New Mexico Hospital
Albuquerque, New Mexico

Cibola Hospital
Grants, New Mexico

Socorro Hospital
Socorro, New Mexico

 

 

Research:

Master’s Thesis:

“Electrophysiological Alterations of Canine Cardiac Purkinje Fibers by Acute Ethanol Administration,” December 1977 .

Paper Presentations:

  • Sigma Xi Chapter, May 1976: “Effects of Ethanol on Canine Cardiac Purkinje Fibers.”
  • National Council on Alcoholism, December 1976, “Electrophysiological Effects of Ethanol on Canine Cardiac Purkinje Fibers.”
  • Medical Education of Substance Abuse Program, July 1977, “Effects of Alcohol on the Heart.”
  • New Mexico-West Texas Urological Association, March 1983, “Management of Penile Incarceration.”
  • Western Section, American Urological Association, July 1983, “Management of Penile Incarceration.”
  • New Mexico-West Texas Urological Association, March 1984, “Down Lung Syndrome.”

 

Publications:

  • “Ethanol Induced Electrophysiological Alterations in Canine Cardiac Purkinje Fibers,” Frederick J. Snoy, Robert J. Harker, William Thies and Kalman Greenspan, Journal of Studies on Alcohol, Vol. 41:11, pp. 1023- 1030. Nov. 1980.
  • “Management of Penile Incarceration,” Frederick J. Snoy, MD, Stephen A. Waner, DDS, Jeffrey R. Woodside, MD, Michael G. Orgel, MD and Thomas A. Borden, MD, Urology, Vol. 24:1, pp. 18-20, July 1984.
  • “Unilateral Pulmonary Edema (Down Lung Syndrome) Following Urologic Surgery,” Frederick J. Snoy, MD and Jeffrey R. Woodside, MD. Journal of Urology, Vol. 132, pp. 776-777, October 1984.

 

Medical, Scientific and Honorary Society Memberships:

  • Alpha Sigma Nu Honor Society
  • American Association of Clinical Urologists
  • American College of Physician Executives
  • American Fertility Society
  • American Medical Association
  • American Urology Association
  • Cooperative Group Outreach Program of the
  • Southwest Oncology Group (SWOG)
  • Greater Albuquerque Medical Association
  • New Mexico Society of Clinical Oncology
  • New Mexico State Medical Society
  • Phi Rho Sigma Medical Fraternity
  • Sigma Xi National Science Fraternity
  • South Central Section of AUA

 

Committees:

Albuquerque Regional Medical Center (formerly St. Joseph Hospital)
Section of Urology
09/85-present

Presbyterian Hospital, Section of Urology
09/85-present

Chief, St. Joseph Hospital, Section of Urology
1994-1995

Chief, Presbyterian Hospital, Section of Urology
1994-1995

St. Joseph Northeast Heights Hospital
Credentials Committee
07/88-06/90

St. Joseph Northeast Heights Hospital
Surgical Audit
07/88-06/91

St. Joseph West Mesa Hospital
Assistant Chief, Department of Surgery
09/85-06/91

St. Joseph West Mesa Hospital
Infection Control Committee
08/85-09/87

St. Joseph West Mesa Hospital
Medical Staff Executive Committee
01/91-1994

St. Joseph West Mesa Hospital
Pharmacy/Therapeutics Committee
09/86-09/87

St. Joseph West Mesa Hospital
Tissue/Transfusion Committee
09/87-06/91

St. Joseph West Mesa Hospital
Credentials Committee
06/91-1992

St. Joseph West Mesa Hospital
Chief, Department of Surgery
06/91-1993

Presbyterian Hospital Cancer Committee
St. Joseph Hospital Rehab
11/88-present

Physician Advisory Committee
07/87-09/89

FHP Physician Advisory Committee
01/86-01/88

NMMS Liaison Committee to Human Services Department
05/87-present

NMMS Public Relations
05/89-01/93

NMMS Reimbursement Task Force Rep.
Human Services Department
05/87-present

GAMA New Members Committee
05/86-05/88

GAMA Delegate to NMMS
1987-1993

Urology Liaison, NM Medicare Carrier
Physician Liaison Committee
1993-1994

Albuquerque Regional Medical Center (formerly St. Joseph Hospital)
Surgical Audit Committee
1998-present

 

 

Clinical Studies Experience:

  • Carbenicillin Prostatitis Study, Veteran’s Administration Hospital Clinic, Patients screened, 20, Patients enrolled, 10, Patients completed, 5, Enrollment period: 12 months
  • Bladder Cancer, BCG Intravesical Immunotherapy Study, SWOG, Patients screened, 10, Patients enrolled, 3, Patients completed, 3, Enrollment period: 12 months
  • Balloon Dilatation of Prostate Safety and Efficacy Study, Patients screened, 15, Patients enrolled, 10, Patients completed, 10, Enrollment period: 12 months
  • Benign Prostatic Hypertrophy Study, SmithKline Beecham, Epristeride Study, Patients screened, 58, Patients enrolled, 18, Patients completed, 12, Enrollment period: 3 ½ months
  • Quinalone Prostatitis Efficacy Study, Pfrzer Pharmaceuticals, Inc., Patients screened, 12, Patients enrolled,4, Patients completed, 4, Enrollment period: 4 ½ months
  • Apomorphine SL Impotence Study, Efficacy and Complications, TAP Pharmaceuticals, Inc., Patients screened, 35, Patients enrolled, 14, Patients completed, 13, Enrollment period: 3 ½ Months
  • Prostate Cancer PSA Study, Bioclinical Partners, Patients screened, 15, Patients enrolled, 8, Patients completed, 8, Enrollment period: 7 months
  • Prostate Cancer PSA Device Study, Diagnostic Oncology CRO, Roche/Boehringer-Mannheim, Patients screened, 60, Patients enrolled, 44, Patients completed, 38, Enrollment period: 4 months
  • Urinary Incontinence Study, Safety and Efficacy, IBAH, Sepracor, Patients screened, 23,Pattents enrolled, 15, Patients completed, 11, Enrollment period: 4 months
  • Prostate Cancer Hormonal Treatment Study, 9904 Phoenix International, Atrix, Patients screened, 13, Patients enrolled, 10, Patients completed, 10, Enrollment period: 5 months
  • Prostatitis Study, Bristol-Myers Squibb, Patients screened, 34, Patients enrolled, 4, Patients completed,10
  • Bladder Cancer Study, ILEX, Patients screened 24, Patients enrolled 1, Patients completed, 1
  • Testosterone Study, Androgel, Assert, Patients screened, 9, Patients enrolled, 9, Patients completed, 9, Enrollment period: 4 months
  • Prostate Cancer Hormonal Treatment Study, Atrix AGL000l, Patients screened,6, Patients enrolled, 6, Patients completed, 6
  • Testosterone Gel Study, Auxilium 202 and 203 (extension), Patients screened, 44, Patients enrolled, 7, Patients completed, 0, Enrollment period: 6 months
  • Testicular Prosthesis Study, Mentor, Patients screened, 6, Patients enrolled, 6, Patients completed-1 year follow-up continues PSA and DNA Sampling, Prostate and Renal Cancer, Genomics, Patients screened, 44, Patients enrolled, 44, Patients completed, 44
  • Overactive Bladder, B & B Clinical Innovations, T’empo, Patients screened, 2, Patients enrolled, 2, Patients completed, 2, Enrollment period: 3 months
  • Benign Prostatic Hypertrophy, Pfizer Pharmaceuticals, Inc., Patients screened,13, Patients enrolled, 7, Patients completed, 7, Enrollment period: 4 months
  • Urgency Incontinence Study, Pfizer Pharmaceuticals, Inc., Patients screened, 14, Patients enrolled, 10, Patients completed, 6, Enrollment period: 5 months
  • Urgency Incontinence Study, Extension Phase, Pfizer Pharmaceuticals, Inc, Patients Enrolled, 6, Patients currently active
  • Prostate Cancer Study, Efficacy and Safety, Atrix AGL0205, Patients screened, 3, Patients enrolled, 3, Patients completed – still active
  • Prostate Cancer Study, Bone Mineral Density,LY, Zometa, Novartis Pharmaceuticals, Inc., Patients screened, 4, Patients enrolled, 4, Patients Completed – still active
  • Females with Lower Urinary Tract Syrnptoms, Boehringer-Ingelheim Pharmaceutical, Inc. 527.25
  • Overactive Bladder Study, Fesoterodine, Schwarz Biosciences, Inc.
  • Overactive B ladder Study, Darifenacin, Pfi zerllrlovarti s Al 37 1 0 42, 2003
  • Erectile Dysfunction, Eli Lilly Tadalafil, 2003 -2004
  • Genital Herpes, Novartis Famvir CFAM 810A, 2003
  • Prostate Cancer Prevention, Vioxx, Merck ViP 2001,2004
  • Women with Stress Incontinence, Duloxetine, Eli l.illy FIJ-US-SBCD, 2004-2005
  • Males with Acute Urinary Retention, Boehringer-lngleheim 527.26, Flomax, 2003-2004
  • Males with Rapid Ejaculation, ALZA 3 studies- 013,014,04 Dapoxetine
  • Prevention of bone fractures in men with prostate cancer and on I-HRH therapy,Toremifene, GTx – G300203, 2004-2005
  • Men with Erectile Dysfunction, Vardenafil, GlaxoSmithKline- 2 studies, 021 and 108. 2004
  • Men with Prostate Cancer in need of first line hormonaltherapy, SiCor GS-121-01. 2004
  • Men with Hormone Refractory Prostate Cancer with Metastatic Disease- Vaccine Study through Therion, 2004-2005
  • Retrospective Study- Bone Metastases National Estimation of Clinical Assessment Resource Evaluation among Prostate Cancer Patients- Novartis 2004
  • Complicated Urinary Tract Infections- Cipro XL for use in Pseudomonas Patients, Bayer 11490, 2004-2005
  • A study of Toremifene Citrate for the prevention of bo.ne fractures in men with Prostate Cancer on Androgen Deprivation Therapy, GTx, 1nc., 2004-2006
  • Men with Rapid Ejaculation- Dapoxetine Withdrawal study for depression. Johnson and Johnson PRE 3002,2004-2005
  • A protocol for blood and urine sample collection from patients undergoing Prostate Biopsies, who do not have previously diagnosed Prostate Cancer. Study is to aid in the Evaluation of in-vitro Diagnostic Devices, 2004-2005
  • A Prostate Cancer Prevention Trial for Men who have been diagnosed with High Grade Prostatic Intraepithelial Neoplasia. GTx, Inc. 2005-2006
  • A protocol for Men with voiding signs and symptoms of Benign Prostatic Hypertrophy, Watson Labs, 2005
  • Open-Label, Expanded Access Program (EAP) Study of 10 mg Atrasentan in Men with Metastatic Hormone-Refractory Prostate Cancer, Abbott Laboratories, 2005
  • A Double-Blind, Multi-Center, Randomized, Placebo-Controlled Study of Safety and Efficacy of Trospim Chloride vs. Placebo, for 12 weeks followed by a 9 month Open-Label treatment phase in patients with overactive bladder, Indevus Pharmaceuticals, 2005-2006
  • A study to evaluate the clinical efficacy and safety of tolterodine ER 4 mg in men who have frequency and urgency, with or without urinary urge incontinence, with or without bladder outlet obstruction, Pfizer, 2005
  • A study to evaluate the efficacy and safety of oxybutynin topical gel for the symptoms of Overactive Bladder, Watson Labs, 2006
  • A Phase 3 study of Denosumab on Prolonging Bone Metastasis-Free Survival in men with Hormone-Refractory Prostate Cancer, Amgen, 2006
  • A study of Denosumab compared with Zoledronic Acid (Zometa) in the treatment of Bone Metastases in men with Hormone-Refractory Prostate Cancer, Amgen, 2006
  • A study assessing the efficacy and safety of Dutasteride in extending the time to progression of Low-Risk, localized Prostate Cancer in men who are candidates lor or undergoing expectant management, GlaxoSmithKline Group, 2006
  • A study comparing the efficacy of Levofloxacin at a different dose levels for different time periods in the treatment of chronic prostatitis, Advanced Biologics, 2006
  • A study using intermittent IM dosage regimens of Cetrorelix in patients with symptomatic BPH, Aeterna Zenlaris, 2006
  • A study for OAB comparing Fesoterodine to Tolterodine and placebo, Pfizer,2007
  • A study for patients with noninvasive bladder cancer, using single dose of EOquin intravesically post surgery, Spectrum, 2007
  • A study investigating the efficacy and safety of a fast dissolving (MELT) formulation of Desmopressin for the treatment of Nocturia,Fening,200T
  • A study using AMG386or placebo in conjunction with Sorifenib for metastatic renal cell carcinoma
  • Three studies assessing the safety and efficacy of Beta-3 Agonist YMl78 for symptoms of overactive bladder, Astellas Pharma Europe, B.V. 2008
  • A study to assess the effects of Pomegranate Extract on rising PSA levels following therapy for prostate cancer, Roll International Corp. 2008
  • A study to assess the efficacy of ABR-215050 placebo-controlled in asymptomatic patients with metastatic castrate resistant prostate cancer, Active Biotech Research 2008
  • A study to assess Silodosin, placebo-controlled in the treatment of subjects with moderate to severe abacterial chronic prostatitis/chronic pelvic pain syndrome, Waston Laboratories, Inc. 2008
  • A study to assess the safety and efficacy of LibiGel® placebo-controlled for the treatment of hypoactive sexual desire disorder in surgically menopausal women. BioSante Pharmaceutical, Inc. 2008
  • A study to assess the safety and efficacy of Deforolimur; inpatients with metastatic prostate cancer, Merck 2009
  • A study to assess safety and efficacy of combining tadalafil with alpha blockers for patients with BPH symptoms, Eli Lilly,2008
  • Two studies assessing Degarelix in men with prostate cancer, comparative study to Leuprilide or Goseralin, Ferring 2009
  • Phase 3, Multicenter, Prospective, Randomized, Parallel-group, placebo controlled double blind clinical evaluation of XX-XXXX for the treatment of BPH, 2010
  • A Multicenter, Randomized, Double-Blind, Placebo and Allopurinol Controlled, Phase 2 Study to evaluate XXX in Medical Management of Sr-rbjects with Hyperuricosuria and Calcium Oxalate Stones, 2010
  • A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center study of the Long-Term safety and efficacy of XXX for the treatment of hypoactive sexual desire disorder in postmenopausal women, 2010
  • A randomized, parallel arm, open-label trial comparing XXX with XXX plus antiandrogen flare protection, in terms of prostate size reduction in prostate cancer patients of intermediate-to-high risk, who require neoadjuvant hormone therapy prior to radiotherapy (curative intent), 2010
  • Phase II, open label, dose finding study of the effect of XXX on total and free testosterone levels in men with prostate cancer compareri to a luteinizing hormone releasing hormone agonist, 2011
  • Phase 2 multicenter prospective open label clinical safety evaluation of re-injection of XXX for the treatment of BPH: Two doses l-7 years apart, Nymox 2012
  • Retrospective follow-up for overall survival in the clinical study; Phase 2 randomized double blind placebo-controlled study to determine the efficacy of XXX in asymptomatic patients with metastatic castrate-resistant prostate cancer, Active Biotech, 2012
  • A self-selection study for the consideration of tamsulosin hydrochloride 0.4 mg in an all comers’s population of adults with bothersome urinary symptoms followed by urological assessment of selected predefined subpopulations, Boeheringer Ingelheim, 2012
  • Phase 2 multicenter prospective open label 2-dose level clinical safety and efficacy evaluation of injection of XXX for the treatment of low risk, localized (T1c) prostate cancer, Nymox, 2012

Dr. Snoy's NM State License